Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis

Joel Malek, Alejandra Martinez, Eliane Mery, Gwenael Ferron, Ruby Huang, Christophe M. Raynaud, Eva Jouve, Jean Paul Thiery, Denis Querleu, Arash Rafii Tabrizi

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background: Ovarian cancer is the most deadly gynecological cancer due to late diagnosis at advanced stage with major peritoneal involvement. To date most research has focused on primary tumor. However the prognosis is directly related to residual disease at the end of the treatment. Therefore it is mandatory to focus and study the biology of meatastatic disease that is most frequently localized to the peritoneal caivty in ovarian cancer.Methods: We used high-density gene expression arrays to investigate gene expression changes between matched primary and metastatic (peritoneal) lesions.Results: Here we show that gene expression profiles in peritoneal metastasis are significantly different than their matched primary tumor and these changes are affected by underlying copy number variation differences among other causes. We show that differentially expressed genes are enriched in specific pathways including JAK/STAT pathway, cytokine signaling and other immune related pathways. We show that underlying copy number variations significantly affect gene expression. Indeed patients with important differences in copy number variation displayed greater gene expression differences between their primary and matched metastatic lesions.Conclusions: Our analysis shows a very specific targeting at both the genomic and transcriptomic level to upregulate certain pathways in the peritoneal metastasis of ovarian cancer. Moreover, while primary tumors use certain pathways we identify distinct differences with metastatic lesions. The variation between primary and metastatic lesions should be considered in personalized treatment of ovarian cancer.

Original languageEnglish
Article number121
JournalJournal of Translational Medicine
Volume10
Issue number1
DOIs
Publication statusPublished - 11 Jun 2012

Fingerprint

Gene expression
Ovarian Neoplasms
Tumors
Neoplasm Metastasis
Gene Expression
Neoplasms
Delayed Diagnosis
Transcriptome
Up-Regulation
Cytokines
Genes
Therapeutics
Research

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis. / Malek, Joel; Martinez, Alejandra; Mery, Eliane; Ferron, Gwenael; Huang, Ruby; Raynaud, Christophe M.; Jouve, Eva; Thiery, Jean Paul; Querleu, Denis; Tabrizi, Arash Rafii.

In: Journal of Translational Medicine, Vol. 10, No. 1, 121, 11.06.2012.

Research output: Contribution to journalArticle

Malek, Joel ; Martinez, Alejandra ; Mery, Eliane ; Ferron, Gwenael ; Huang, Ruby ; Raynaud, Christophe M. ; Jouve, Eva ; Thiery, Jean Paul ; Querleu, Denis ; Tabrizi, Arash Rafii. / Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis. In: Journal of Translational Medicine. 2012 ; Vol. 10, No. 1.
@article{fb443c28e66c49819486e9c7fd8b9df6,
title = "Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis",
abstract = "Background: Ovarian cancer is the most deadly gynecological cancer due to late diagnosis at advanced stage with major peritoneal involvement. To date most research has focused on primary tumor. However the prognosis is directly related to residual disease at the end of the treatment. Therefore it is mandatory to focus and study the biology of meatastatic disease that is most frequently localized to the peritoneal caivty in ovarian cancer.Methods: We used high-density gene expression arrays to investigate gene expression changes between matched primary and metastatic (peritoneal) lesions.Results: Here we show that gene expression profiles in peritoneal metastasis are significantly different than their matched primary tumor and these changes are affected by underlying copy number variation differences among other causes. We show that differentially expressed genes are enriched in specific pathways including JAK/STAT pathway, cytokine signaling and other immune related pathways. We show that underlying copy number variations significantly affect gene expression. Indeed patients with important differences in copy number variation displayed greater gene expression differences between their primary and matched metastatic lesions.Conclusions: Our analysis shows a very specific targeting at both the genomic and transcriptomic level to upregulate certain pathways in the peritoneal metastasis of ovarian cancer. Moreover, while primary tumors use certain pathways we identify distinct differences with metastatic lesions. The variation between primary and metastatic lesions should be considered in personalized treatment of ovarian cancer.",
author = "Joel Malek and Alejandra Martinez and Eliane Mery and Gwenael Ferron and Ruby Huang and Raynaud, {Christophe M.} and Eva Jouve and Thiery, {Jean Paul} and Denis Querleu and Tabrizi, {Arash Rafii}",
year = "2012",
month = "6",
day = "11",
doi = "10.1186/1479-5876-10-121",
language = "English",
volume = "10",
journal = "Journal of Translational Medicine",
issn = "1479-5876",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Gene expression analysis of matched ovarian primary tumors and peritoneal metastasis

AU - Malek, Joel

AU - Martinez, Alejandra

AU - Mery, Eliane

AU - Ferron, Gwenael

AU - Huang, Ruby

AU - Raynaud, Christophe M.

AU - Jouve, Eva

AU - Thiery, Jean Paul

AU - Querleu, Denis

AU - Tabrizi, Arash Rafii

PY - 2012/6/11

Y1 - 2012/6/11

N2 - Background: Ovarian cancer is the most deadly gynecological cancer due to late diagnosis at advanced stage with major peritoneal involvement. To date most research has focused on primary tumor. However the prognosis is directly related to residual disease at the end of the treatment. Therefore it is mandatory to focus and study the biology of meatastatic disease that is most frequently localized to the peritoneal caivty in ovarian cancer.Methods: We used high-density gene expression arrays to investigate gene expression changes between matched primary and metastatic (peritoneal) lesions.Results: Here we show that gene expression profiles in peritoneal metastasis are significantly different than their matched primary tumor and these changes are affected by underlying copy number variation differences among other causes. We show that differentially expressed genes are enriched in specific pathways including JAK/STAT pathway, cytokine signaling and other immune related pathways. We show that underlying copy number variations significantly affect gene expression. Indeed patients with important differences in copy number variation displayed greater gene expression differences between their primary and matched metastatic lesions.Conclusions: Our analysis shows a very specific targeting at both the genomic and transcriptomic level to upregulate certain pathways in the peritoneal metastasis of ovarian cancer. Moreover, while primary tumors use certain pathways we identify distinct differences with metastatic lesions. The variation between primary and metastatic lesions should be considered in personalized treatment of ovarian cancer.

AB - Background: Ovarian cancer is the most deadly gynecological cancer due to late diagnosis at advanced stage with major peritoneal involvement. To date most research has focused on primary tumor. However the prognosis is directly related to residual disease at the end of the treatment. Therefore it is mandatory to focus and study the biology of meatastatic disease that is most frequently localized to the peritoneal caivty in ovarian cancer.Methods: We used high-density gene expression arrays to investigate gene expression changes between matched primary and metastatic (peritoneal) lesions.Results: Here we show that gene expression profiles in peritoneal metastasis are significantly different than their matched primary tumor and these changes are affected by underlying copy number variation differences among other causes. We show that differentially expressed genes are enriched in specific pathways including JAK/STAT pathway, cytokine signaling and other immune related pathways. We show that underlying copy number variations significantly affect gene expression. Indeed patients with important differences in copy number variation displayed greater gene expression differences between their primary and matched metastatic lesions.Conclusions: Our analysis shows a very specific targeting at both the genomic and transcriptomic level to upregulate certain pathways in the peritoneal metastasis of ovarian cancer. Moreover, while primary tumors use certain pathways we identify distinct differences with metastatic lesions. The variation between primary and metastatic lesions should be considered in personalized treatment of ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=84861990353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861990353&partnerID=8YFLogxK

U2 - 10.1186/1479-5876-10-121

DO - 10.1186/1479-5876-10-121

M3 - Article

VL - 10

JO - Journal of Translational Medicine

JF - Journal of Translational Medicine

SN - 1479-5876

IS - 1

M1 - 121

ER -